Therapeutic Targeting of Apoptosis Inhibitor of Macrophage/CD5L in Sepsis

被引:30
作者
Gao, Xun [1 ,2 ]
Yan, Xingxing [1 ]
Yin, Yibing [2 ]
Lin, Xue [1 ]
Zhang, Qun [3 ]
Xia, Yun [1 ]
Cao, Ju [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Lab Med, 1 Youyi Rd, Chongqing 400016, Peoples R China
[2] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China
[3] Chongqing Med Univ, Affiliated Childrens Hosp, Clin Labs Ctr, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
apoptosis inhibitor of macrophage; sepsis; inflammation; IL-10; homeostasis; ANTIINFLAMMATORY CYTOKINE PROFILE; INTENSIVE-CARE-UNIT; T-CELLS; LUNG; ACTIVATION; INTERLEUKIN-10; MORTALITY; INJURY; MICE; PERITONITIS;
D O I
10.1165/rcmb.2018-0272OC
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The factors involved in disturbing host homeostasis during sepsis are largely unknown. We sought to determine the immunopathological role of apoptosis inhibitor of macrophage (AIM)/CD5L in sepsis. Here, we show that blockade of AIM led to significantly increased survival after experimental sepsis, and it decreased local and systemic inflammation, reduced tissue injury, and inhibited bacterial dissemination in the blood, in particular at later time points. Supplementation of recombinant AIM in sepsis resulted in increased tissue injury, amplified inflammation, increased bacteremia, and worsened mortality. Interestingly, the most important difference in the production of cytokines and chemokines after in vivo AIM blockade or AIM administration during sepsis was IL-10. In vitro, AIM enhanced IL-10 production from macrophages, neutrophils, or lymphocytes. In vivo, the beneficial effects of AIM blockade and the detrimental effects of AIM addition on experimental sepsis were ablated by treatment with recombinant IL-10 and neutralizing anti-IL-10 antibodies, respectively. This study is the first to identify AIM as an important mediator in disturbing host homeostasis in sepsis.
引用
收藏
页码:323 / 334
页数:12
相关论文
共 46 条
[11]   Strategies to improve drug development for sepsis [J].
Fink, Mitchell P. ;
Warren, H. Shaw .
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (10) :741-758
[12]   Assessment of Global Incidence and Mortality of Hospital-treated Sepsis [J].
Fleischmann, Carolin ;
Scherag, Andre ;
Adhikari, Neill K. J. ;
Hartog, Christiane S. ;
Tsaganos, Thomas ;
Schlattmann, Peter ;
Angus, Derek C. ;
Reinhart, Konrad .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193 (03) :259-272
[13]   Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: A marker for prognosis and future therapeutic options [J].
Gogos, CA ;
Drosou, E ;
Bassaris, HP ;
Skoutelis, A .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :176-180
[14]   Enhanced understanding of the host-pathogen interaction in sepsis: new opportunities for omic approaches [J].
Goh, Cyndi ;
Knight, Julian C. .
LANCET RESPIRATORY MEDICINE, 2017, 5 (03) :212-223
[15]   Apoptosis inhibitor expressed by macrophages tempers autoimmune colitis and the risk of colitis-based carcinogenesis in TCRα-/- mice [J].
Haruta, Ikuko ;
Shibata, Noriyuki ;
Kato, Yoichiro ;
Tanaka, Masanori ;
Kobayashi, Makio ;
Oguma, Hidetoshi ;
Shiratori, Keiko .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) :549-556
[16]   Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+CD25+Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival [J].
Hiraki, Shuhichi ;
Ono, Satoshi ;
Tsujimoto, Hironori ;
Kinoshita, Manabu ;
Takahata, Risa ;
Miyazaki, Hiromi ;
Saitoh, Daizoh ;
Hase, Kazuo .
SURGERY, 2012, 151 (02) :313-322
[17]   IFN-β Improves Sepsis-related Alveolar Macrophage Dysfunction and Postseptic Acute Respiratory Distress Syndrome-related Mortality [J].
Hiruma, Takahiro ;
Tsuyuzaki, Hitoshi ;
Uchida, Kanji ;
Trapnell, Bruce C. ;
Yamamura, Yoshiro ;
Kusakabe, Yoshiomi ;
Totsu, Tokie ;
Suzuki, Takuji ;
Morita, Shigeki ;
Doi, Kent ;
Noiri, Eisei ;
Nakamura, Kensuke ;
Nakajima, Susumu ;
Yahagi, Naoki ;
Morimura, Naoto ;
Chang, Kyungho ;
Yamada, Yoshitsugu .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2018, 59 (01) :45-55
[18]   Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: Dependence on timing of immunomodulating intervention [J].
Kalechman, Y ;
Gafter, U ;
Gal, R ;
Rushkin, G ;
Yan, DH ;
Albeck, M ;
Sredni, B .
JOURNAL OF IMMUNOLOGY, 2002, 169 (01) :384-392
[19]   Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10 [J].
Kelly-Scumpia, Kindra M. ;
Scumpia, Philip O. ;
Delano, Matthew J. ;
Weinstein, Jason S. ;
Cuenca, Alex G. ;
Wynn, James L. ;
Moldawer, Lyle L. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (02) :319-326
[20]   Activation of CXCR2 by Extracellular Matrix Degradation Product Acetylated Pro-Gly-Pro Has Therapeutic Effects against Sepsis [J].
Kim, Sang Doo ;
Lee, Ha Young ;
Shim, Jae Woong ;
Kim, Hak Jung ;
Yoo, Young Hyun ;
Park, Joon Seong ;
Baek, Suk-Hwan ;
Zabel, Brian A. ;
Bae, Yoe-Sik .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (02) :243-251